REG - Proteome Sciences - Substantial contract for Proteome Sciences

Proteome SciencesAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251208:nRSH5454Ka&default-theme=true

RNS Number : 5454K  Proteome Sciences PLC  08 December 2025

 

 

Prior to publication, the information contained within this announcement was
deemed by the Company to constitute inside information as stipulated under the
UK Market Abuse Regulations. With the publication of this announcement, this
information is now considered to be in the public domain.

8 December 2025

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Substantial contract for Proteome Sciences

Proteome Sciences (AIM:PRM), is pleased to announce that the Company has
secured a third contract from a US biopharmaceutical company using the
Company's mass spectrometry services to develop a new assay at the company's
facilities in Frankfurt, Germany in anticipation of starting a new clinical
trial programme next year.

The initial contract will be designed to comply with Good Clinical Laboratory
Practice ("GCLP") accreditation and when completed, the new assay will be used
to analyse samples from a forthcoming clinical trial due to start at the end
of Q1 2026.   The next phases of work are anticipated to be similar to the
contracts announced in February 2025.  A proportion of the work should be
completed in the current financial year, with the remainder by the end of Q1
2026.

Commenting on the contract, Richard Dennis, Chief Commercial Officer of
Proteome Sciences said:

"We expected to receive additional contracts from the same customer and the
targeted assay that we develop is designed to perform under GCLP compliance to
monitor drug performance in the new clinical trial planned for early 2026. As
in 2024, we continue to see increasing interest for GCLP contracts from other
major biopharma clients both in the US and Europe and we hope to secure
additional orders in 2026 and 2027."

- Ends -

For further information:

 Proteome Sciences plc
 Dr. Ian Pike, Chief Scientific Officer                         Tel: +44 (0)20 7043 2116
 Richard Dennis, Chief Commercial Officer

 SP Angel Corporate Finance LLP  (Nominated Adviser & Broker)
 David Hignell/Richard Morrisom/Josh Ray  (Corporate Finance)   Tel: +44 (0) 20 3470 0470

 Vadim Alexandre (Corporate Broking)

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and
contextualising new targets and defining mechanisms of biological activity,
while analysis using Super-Depletion and TMTcalibrator™ provides access to
over 8,500 circulating plasma proteins for the discovery of disease-related
biomarkers. Targeted assay development using mass spectrometry delivers high
sensitivity, interference-free biomarker analyses in situations where standard
ELISA assays are not available.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTEASAKEFNSFFA



            Copyright 2019 Regulatory News Service, all rights reserved